Cutaneous wound healing and tissue repair — compounds assessed
The 7 compounds the Institute assesses in cutaneous wound healing and tissue repair.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Small controlled dermatological studies report improvements in skin roughness, wrinkle depth and collagen density with topical application over 12 weeks — The topical dermatological evidence is the strongest in this compound's file. It is nonetheless…
Low -
A phase 1/2 trial of intralesional LL-37 in hard-to-heal venous leg ulcers reported greater ulcer-area reduction at intermediate doses than at the highest dose — A genuine controlled clinical trial exists. The non-monotonic dose response is consistent with…
Low -
Phase 2 trials in dry-eye disease, epidermolysis bullosa and venous stasis ulcers reported signals on some secondary endpoints without meeting primary endpoints consistently — A genuine phase 2 clinical programme exists, which distinguishes this compound from…
Low -
Synthetic pentadecapeptide derived from a gastric juice protein sequence0 contributing trialsfull monograph
No randomised controlled human trial identified — Preclinical only.
Very low -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)0 contributing trialsfull monograph
No randomised human evidence identified — Preclinical cytoprotection studies exist; no human trial does.
Very low -
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone0 contributing trialsfull monograph
No randomised controlled human trial identified — Preclinical and small uncontrolled dermatological reports only.
Very low -
Clinical trials of the full-length thymosin beta-4 protein were conducted in epidermolysis bullosa and in dry-eye disease; results did not support marketing authorisation — Critically, those trials used the full-length 43-residue protein, not the heptapeptide…
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018;19(7):1987. doi:10.3390/ijms19071987 · PMID 29986520
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.